168 related articles for article (PubMed ID: 18849502)
1. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases.
Luboldt W; Küfer R; Blumstein N; Toussaint TL; Kluge A; Seemann MD; Luboldt HJ
Radiology; 2008 Dec; 249(3):1017-25. PubMed ID: 18849502
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases?
Lecouvet FE; Vande Berg BC; Malghem J; Omoumi P; Simoni P
Radiology; 2009 Aug; 252(2):624. PubMed ID: 19703896
[No Abstract] [Full Text] [Related]
3. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
[TBL] [Abstract][Full Text] [Related]
4. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
[TBL] [Abstract][Full Text] [Related]
6. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
7. MRI and PET/CT of patients with bone metastases from breast carcinoma.
Grankvist J; Fisker R; Iyer V; Fründ ET; Simonsen C; Christensen T; Stenbygaard L; Ewertz M; Larsson EM
Eur J Radiol; 2012 Jan; 81(1):e13-8. PubMed ID: 21227614
[TBL] [Abstract][Full Text] [Related]
8. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
10. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
[TBL] [Abstract][Full Text] [Related]
11. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
[TBL] [Abstract][Full Text] [Related]
12. [Metabolic and osteogenic pattern of prostate cancer bone metastases].
García JR; Riera E; Valls E; Soler M; Moragas M; Lomeña F
Rev Esp Med Nucl Imagen Mol; 2013 Jan; 32(1):33-6. PubMed ID: 22835661
[TBL] [Abstract][Full Text] [Related]
13. Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy.
Goudarzi B; Kishimoto R; Komatsu S; Ishikawa H; Yoshikawa K; Kandatsu S; Obata T
Magn Reson Imaging; 2010 Apr; 28(3):372-9. PubMed ID: 20106624
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of malignant tumor metabolism: whole-body image fusion of DWI/CT vs. PET/CT.
Reiner CS; Fischer MA; Hany T; Stolzmann P; Nanz D; Donati OF; Weishaupt D; von Schulthess GK; Scheffel H
Acad Radiol; 2011 Aug; 18(8):940-6. PubMed ID: 21718953
[TBL] [Abstract][Full Text] [Related]
15. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations.
Huellner MW; Appenzeller P; Kuhn FP; Husmann L; Pietsch CM; Burger IA; Porto M; Delso G; von Schulthess GK; Veit-Haibach P
Radiology; 2014 Dec; 273(3):859-69. PubMed ID: 25102372
[TBL] [Abstract][Full Text] [Related]
16. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA
Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847
[TBL] [Abstract][Full Text] [Related]
17. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
[TBL] [Abstract][Full Text] [Related]
18. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
19. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.
Pasoglou V; Michoux N; Peeters F; Larbi A; Tombal B; Selleslagh T; Omoumi P; Vande Berg BC; Lecouvet FE
Radiology; 2015 Apr; 275(1):155-66. PubMed ID: 25513855
[TBL] [Abstract][Full Text] [Related]
20. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
